Investors are focused on whether Eli Lilly and Co. can continue dividend payments when patent expirations hit in the new few
years and whether the company's drug development pipeline can replace lost revenue.
Indianapolis-based drugmaker Eli Lilly and Co. recorded profits of $1.3 billion, or $1.22 per share, during the three months
ended June 30,
even after paying $27 million in severance to laid off employees.
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.
The global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.
The two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
David Stocum is the director of the Center for Regenerative Biology and Medicine at the IUPUI School of Science.
He and his team are studying how amphibians regenerate parts of their bodies to see if there are ways to induce humans to
regenerate tissue that is lost or damaged. The center has about 20 researchers and funding of about $14 million to fuel its
quest.
A firm that may have developed a breakthrough yeast for ethanol production has landed new investment and high-octane board
members. Two-year-old Xylogenics Inc. also says it plans to license its first bioengineered yeast later this year.
The Indianapolis-based forensics, clinical and pharmaceutical testing firm, led by CEO Michael Evans, plans to invest $74
million to acquire and equip
an existing 90,000-square-foot building in Woodland Corporate Park near West 79th Street and Interstate 465.
Health care, plastics, other fundamental consumer needs kept some companies on upswings.
The Metropolitan Development Commission voted Wednesday afternoon to release nearly $4 million to
improve
the historic building in downtown Indianapolis.
Having invested in 10 companies since 2005 and with its $6 million pot of money running low, the Indiana Seed Fund is nearing
a crossroads.
Not-for-profit launched last year by BioCrossroads and Indiana’s orthopedic companies names Zimmer Inc. executive Brad Bishop
to lead the initiative.
Former collaborator alleges firm breached its agreement with him and refused to pay royalty income.
A Purdue University-based company has reached a deal giving Chinese and Danish firms access to a patented product that makes
it easier to turn wood chips, grasses and other agricultural wastes into ethanol.
AgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual
property, and begin learning how to make a drug into a once-a-day pill.
In the past few years, a handful of cold storage facilities have sprouted locally by playing to Indianapolis' strengths
in warehousing and life sciences.
Bioanalytical Systems Inc. narrowed its losses in the second fiscal quarter despite a 2 percent drop in revenue, the West
Lafayette-based contract research firm said late last week.
West Lafayette-based Bioanalytical Systems Inc. has promoted Anthony S. Chilton to CEO following the retirement of top executive
Richard M. Shepperd earlier this year.
Bloomington led the nation as the No. 1 small city in medical devices and equipment.
There has been a noticeable uptick in the level of health care real estate development activity this year.
